Biocon reported net income of Rs 1.38 bn, down 18% year-on-year for the second quarter. It missed the average analyst estimate. It recorded a revenue of Rs 19.45 bn, 11% rise as compared to the previous year, above the analysts’ estimates. There is an increase of 35% in the company’s Ebitda to Rs 5.51 bn. Kiran Mazumdar Shaw, Executive Chairperson, Biocon talks about the Q2 earnings and what will be the future trends of company’s segments as pandemic restrictions are lessening. Watch the full interview here on ET NOW to know more on biosimilars, generics and research & development verticals.